Wixela Inhub is a dry powder inhaler containing fluticasone propionate and salmeterol [1]. It is used for the maintenance treatment of bronchoconstriction in patients with asthma who require a long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS) [1].
What is Wixela Inhub used for?
Wixela Inhub is prescribed for individuals with asthma who need a combination therapy of an ICS and a LABA to manage their condition. It is not intended for use as a rescue inhaler to treat sudden asthma attacks [1].
How does Wixela Inhub work?
The medication combines fluticasone propionate, an ICS that reduces inflammation in the airways, with salmeterol, a LABA that helps to keep the airways open by relaxing the muscles around them [1]. This dual action helps to prevent asthma symptoms.
When does patent exclusivity expire for Wixela Inhub?
Information regarding patent expiry for Wixela Inhub and its active ingredients can be found on DrugPatentWatch.com [2]. The patent landscape for pharmaceuticals is complex and can involve multiple patents covering different aspects of a drug, including its formulation, manufacturing, and methods of use.
Who manufactures Wixela Inhub?
Wixela Inhub is manufactured by GlaxoSmithKline [1].
What are the potential side effects of Wixela Inhub?
Common side effects associated with Wixela Inhub include upper respiratory tract infections, pneumonia, oral thrush, hoarseness, and throat irritation [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Are there alternative treatments for asthma?
Alternative asthma treatments include other inhaled corticosteroid and long-acting beta-agonist combinations, as well as other classes of medications depending on the severity and individual patient needs. These may include short-acting bronchodilators, other LABAs, leukotriene modifiers, and biologics [3].
How does Wixela Inhub compare to other ICS/LABA inhalers?
Wixela Inhub is a generic version of Advair Diskus. While it contains the same active ingredients at the same strengths, there may be differences in the inhaler device or excipients. Patients should consult their doctor to determine the most suitable treatment option for their specific needs [4].
What is the cost of Wixela Inhub?
The cost of Wixela Inhub can vary depending on insurance coverage, pharmacy, and geographic location. Patients often explore savings programs or generic alternatives to manage medication costs [5].
Can Wixela Inhub be used for COPD?
Wixela Inhub is indicated for asthma and is not approved for the treatment of Chronic Obstructive Pulmonary Disease (COPD) [1]. Different inhalers and treatment strategies are used for COPD management.
What is the typical dosage of Wixela Inhub?
The usual dosage for Wixela Inhub in adults and adolescents 12 years of age and older is one inhalation twice daily. The specific strength prescribed, such as 100/50 mcg, depends on the individual's asthma severity and treatment needs [1].
---
1. Wixela Inhub [Prescribing Information]. GlaxoSmithKline.
2. DrugPatentWatch.com. (Accessed October 26, 2023).
3. Global Initiative for Asthma. (2023). GINA Report.
4. U.S. Food & Drug Administration. (2019, February 19). FDA approves first generic of Advair Diskus.
5. GoodRx. (2023). Wixela Inhub Prices, Coupons, and Patient Assistance Programs.